{"cluster": 57, "subcluster": 11, "abstract_summ": "On March 28, 2020, in response to the rapidly accelerating COVID-19 pandemic, U.S FDA issued emergency use authorization for hydroxychloroquine (HCQ) in hospitalized COVID-19 patients based on limited in-vitro and anecdotal clinical data.Our analysis of a large retrospective cohort of hospitalized COVID-19 patients treated with HCQ did not show benefits in mortality or the need for mechanical ventilation when compared to a matched cohort of patients who did not receive HCQ.Background: Hydroxychloroquine has been touted as a COVID-19 treatment.Results: We recorded 21 COVID-19 pneumonia patients of whom 19 opted for treatment.Conclusions Among patients hospitalized with COVID-19, this retrospective study did not identify any significant reduction in mortality or in the need for mechanical ventilation with hydroxychloroquine treatment with or without azithromycin.Conclusions: This observational cohort study suggests hydroxychloroquine, either alone or in combination with azithromycin, was not associated with a survival benefit among hospitalized COVID-19 patients.", "title_summ": "Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record NetworkHydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational StudyViral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with hydroxychloroquine and azithromycin in Lebanon.Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progressionObservational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19", "title_abstract_phrases": "Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record NetworkOn March 28, 2020, in response to the rapidly accelerating COVID-19 pandemic, U.S FDA issued emergency use authorization for hydroxychloroquine (HCQ) in hospitalized COVID-19 patients based on limited in-vitro and anecdotal clinical data.Our analysis of a large retrospective cohort of hospitalized COVID-19 patients treated with HCQ did not show benefits in mortality or the need for mechanical ventilation when compared to a matched cohort of patients who did not receive HCQ.Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational StudyBackground: Hydroxychloroquine has been touted as a COVID-19 treatment.Results: We recorded 21 COVID-19 pneumonia patients of whom 19 opted for treatment.Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19BACKGROUND: Despite limited and conflicting data on the use of hydroxychloroquine in patients with Covid-19, the U.S. Food and Drug Administration has authorized the emergency use of this drug when clinical trials are unavailable or infeasible.Conclusions: This observational cohort study suggests hydroxychloroquine, either alone or in combination with azithromycin, was not associated with a survival benefit among hospitalized COVID-19 patients."}